| 1L |
First line |
| 2L |
Second line |
| 3L |
Third line |
| 4L |
Fourth line |
| Abs |
Absolute |
| ACIC |
Academic and commercial in confidence |
| ADaM |
Analysis Data Model |
| AE |
Adverse event |
| ASCO |
American Society Of Clinical Oncology |
| aRCC |
Advanced renal cell carcinoma |
| AUC |
Area under the curve |
| BSC |
Best supportive care |
| cabo |
cabozantinib |
| CIC |
Commercial in confidence |
| CDF |
Cancer Drugs Fund |
| CE |
Cost effectiveness |
| CEA |
Cost effectiveness analysis |
| CODA |
Convergence diagnosis and output analysis |
| cPAS |
Confident patient access scheme |
| DSU |
Decision support unit |
| EAG |
External assessment group |
| EOL |
End of life |
| EOM-RCC |
Exeter Oncology Model: Renal Cell Carcinoma edition |
| ERG |
Evidence Review Group |
| evero |
Everolimus |
| FAD |
Final appraisal document |
| fav |
Favourable |
| FP |
Fractional polynomial |
| FP NMA |
Fractional polynomial network meta-analysis |
| Gen |
general |
| HFS |
Hand-foot syndrome |
| HPC |
High-performance computing |
| HR |
Hazard ratio |
| HRQL |
Health-related quality of life |
| HTA |
Health technology assessment |
| ICER |
Incremental Cost-Effectiveness Ratio |
| int |
Intermediate |
| IMDC |
International Metastatic Renal Cell Carcinoma Database Consortium |
| IO |
Immuno-oncology |
| IPD |
Individual patient data |
| ipi |
Ipilimumab |
| IV |
Intravenous |
| KM |
Kaplan-Meier |
| lenv |
Lenvatinib |
| LY |
Life year(s) |
| LYG |
Life year(s) gained |
| MRC |
Medical Research Council |
| MRU |
Medical Resource Use |
| MTA |
Multiple technology appraisal |
| NHS |
National Health Service |
| NHSE |
National Health ServiceEngland |
| NICE |
National Institute for Health and Care Excellence |
| NIHR |
National Institute for Health and Care Research |
| nivo |
Nivolumab |
| NMA |
Network meta-analysis |
| ONS |
Office for National Statistics |
| OS |
Overall survival |
| PartSA |
Partitioned-survival analysis |
| PAS |
Patient access scheme |
| PATT |
Proportionate approach to technology appraisals |
| pazo |
pazopanib |
| PD |
Progressed disease |
| pem |
Pembrolizumab |
| PenTAG |
Peninsula Technology Assessment Group |
| PFS |
Progression-free survival |
| PH |
Proportional hazards |
| PH NMA |
Proportional hazards network meta-analysis |
| PLD |
Patient-level data |
| PLMT |
Population + Line + Molecule + Trial |
| PLMTE |
Population + Line + Molecule + Trial + Endpoint |
| pop |
Population |
| PPS |
Post-progression survival |
| prop |
Proportional |
| PSA |
Probablistic sensitivity analysis |
| PSM |
Progressed state membership |
| QALY |
Quality-adjusted life year(s) |
| QC |
Quality check |
| RCC |
Renal cell carcinoma |
| RDI |
Relative dosing intensity |
| RE |
Relative efficacy |
| ROC |
Renal Oncology Collaborative |
| RWE |
Real-world evidence |
| SF |
Shortfall |
| SOC |
Standard of care |
| st |
Survival at time t |
| STA |
Single technology appraisal |
| suni |
Sunitinib |
| TA |
Technology appraisal |
| tivo |
Tivozanib |
| TKI |
Tyrosine Kinase Inhibitor |
| TP matrices |
Treatment pathway matrices |
| TSD |
Technical Support Document |
| TTD |
Time to discontinuation |
| TOT |
Time on treatment |
| TTNT |
Time to next treatment |
| TTP |
Time to progression |
| TuotA |
Time unit of the analysis |
| UK |
United Kingdom |
| VEGF |
Vascular endothelial growth factor |
| vs |
Versus |
| WTP |
Willingness to pay |